infl
uenza
viru
call
pandem
emerg
mexico
unit
state
spread
rapidli
june
world
health
organ
declar
pandem
alert
indic
global
pandem
earliest
viru
isol
sensit
neuraminidas
inhibitor
nai
zanamivir
oseltamivir
resist
inhibitor
amantadin
rimantadin
thu
nai
use
global
treatment
prophylaxi
pandem
viru
infl
ection
oseltamivirresist
pandem
fi
rst
detect
japan
denmark
hong
kong
mayjun
sinc
sporad
identifi
ed
around
world
pandem
virus
specifi
c
na
mutat
histidinetotyrosin
substitut
amino
acid
posit
number
confer
resist
oseltamivir
report
pandem
case
octob
associ
treatment
associ
postexposur
prophylaxi
naiuntreat
patient
unknown
associ
preliminari
global
nai
surveil
show
pandem
infect
among
clinic
specimen
thu
global
frequenc
pandem
januari
report
indic
humantohuman
transmiss
pandem
limit
oseltamivir
treatment
prophylaxi
could
lead
emerg
pandem
viru
report
show
japan
account
world
oseltamivir
consumpt
oseltamivir
suppli
japan
season
data
chugai
co
ltd
tokyo
japan
thu
japan
highrisk
environ
develop
pandem
viru
drug
use
pressur
emerg
resist
alarm
season
infl
uenza
virus
rapidli
spread
worldwid
acquir
capac
humantohuman
transmiss
addit
season
japan
almost
case
infl
uenza
caus
pandem
virus
figur
thu
close
surveil
must
maintain
detect
pandem
chang
transmiss
genet
antigen
characterist
monitor
character
clinic
specimen
collect
japan
may
patient
pandem
na
sequenc
nai
assay
found
pandem
virus
mutat
infl
uenza
sentinel
clinic
nonsentinel
institut
send
origin
sampl
local
public
health
laboratori
detect
viru
isol
total
clinic
specimen
compris
origin
sampl
n
clinic
isol
n
underw
either
full
partial
nt
na
sequenc
detect
mutat
sampl
case
collect
oseltamivir
exposur
associ
oseltamivir
use
associ
zanamivir
use
antiviru
treatment
statu
unknown
collect
pandem
isol
randomli
select
os
isol
local
public
health
laboratori
repres
os
pandem
isol
underw
na
inhibit
assay
os
virus
test
full
na
hemagglutin
ha
sequenc
os
intern
gene
sequenc
os
hemagglutin
inhibit
hi
test
os
phylogenet
tree
na
ha
gene
construct
neighborjoin
method
phylogenet
tree
construct
use
repres
os
pandem
isol
sever
prefectur
japan
sequenc
inform
pandem
countri
download
global
initi
share
avian
infl
uenza
data
gisaid
genbank
amino
acid
posit
phylogenet
tree
describ
number
chemiluminesc
nai
assay
perform
nastar
kit
appli
biosystem
tokyo
japan
briefl
fi
nal
drug
concentr
emerg
infecti
diseas
wwwcdcgoveid
vol
boxandwhisk
plot
use
determin
cutoff
valu
nairesist
outlier
sensit
virus
box
contain
result
repres
middl
quartil
length
box
show
interquartil
rang
iqr
cutoff
valu
defi
ned
upper
quartil
interquartil
rang
percentil
statist
analys
pandem
virus
mutat
exclud
overal
popul
hi
test
perform
evalu
reactiv
ferret
antiserum
vaccin
strain
describ
manual
effi
caci
ferret
postinfect
antiserum
egggrown
use
refer
antiserum
treat
receptordestroy
enzym
ii
denka
seiken
tokyo
japan
adsorb
turkey
erythrocyt
test
prevent
nonspecifi
c
reaction
suspens
turkey
erythrocyt
use
hi
test
clinic
specimen
isol
may
collect
prefectur
japan
mutat
detect
na
sequenc
total
pandem
virus
possess
n
mix
n
mutat
figur
pandem
emerg
sporad
sever
prefectur
detect
period
sever
month
figur
casepati
oseltamivir
treatment
zanamivir
treatment
naiuntreat
treatment
histori
unknown
case
pandem
associ
oseltamivir
treatment
postexposur
prophylaxi
occur
naiuntreat
patient
thu
oseltamivir
treatment
prophylaxi
like
acceler
emerg
pandem
relationship
time
sampl
day
oseltamivir
treatment
pandem
detect
show
pandem
gener
detect
least
day
oseltamivir
treatment
tabl
casepati
male
year
year
year
year
underli
medic
condit
known
chronic
underli
medic
condit
pulmonari
neurolog
blood
diabet
kidney
diseas
immunocompromis
condit
almost
pandem
case
emerg
sporad
epidemiolog
link
howev
case
humantohuman
transmiss
suspect
one
observ
niigata
prefectur
children
hospit
room
infect
pandem
viru
within
day
symptom
develop
fi
rst
girl
octob
suspect
instanc
humantohuman
transmiss
occur
tottori
prefectur
boy
symptom
develop
decemb
pandem
viru
isol
sampl
collect
day
oseltamivir
use
howev
patient
brother
infect
pandem
viru
receiv
oseltamivir
sinc
decemb
although
sampl
person
avail
pandem
like
emerg
patient
transmit
detail
epidemiolog
inform
avail
person
pandem
infect
untreat
nai
besid
case
tottori
prefectur
anoth
occur
oita
prefectur
index
patient
mild
cough
begin
juli
typic
total
specimen
test
neuraminidas
inhibitor
treatment
histori
avail
specimen
patient
receiv
oseltamivir
treatment
indic
prophylact
use
eg
total
use
prophylaxi
repres
sampl
collect
within
h
oseltamivir
use
figur
calcul
precis
ic
valu
mix
popul
nairesist
sensit
virus
possibl
mix
isol
exclud
overal
popul
purpos
statist
analysi
nai
data
summar
tabl
hi
test
perform
estim
reactiv
os
n
pandem
data
present
provid
evid
sustain
spread
pandem
japan
valu
mix
sampl
exclud
overal
popul
statist
analysi
isol
sd
ic
valu
control
season
influenza
virus
determin
independ
experi
oseltamivir
zanamivir
studi
clinic
specimen
collect
naiuntreat
naitreat
patient
later
sampl
collect
exert
select
pressur
drug
treatment
howev
frequenc
detect
pandem
low
os
pandem
isol
genet
antigen
indistinguish
current
vaccin
would
expect
effect
recent
pandem
evid
reassort
season
infl
uenza
viru
detect
immunocompet
patient
infect
pandem
show
typic
uncompl
infl
uenza
symptom
similar
caus
os
pandem
earli
report
suggest
worldwid
consumpt
oseltamivir
occur
japan
longterm
nai
surveil
japan
previou
nai
surveil
show
low
frequenc
resist
virus
suggest
transmiss
virus
select
drug
pressur
remark
reduc
howev
begin
novemb
unexpectedli
high
frequenc
season
infl
uenza
virus
mutat
detect
europ
isol
naiuntreat
patient
transmiss
os
infl
uenza
result
rapid
global
dissemin
contrast
even
season
infl
uenza
detect
rare
japan
despit
high
level
oseltamivir
use
howev
infl
uenza
viru
detect
far
higher
frequenc
next
year
thu
pattern
oseltamivir
use
correspond
emerg
widespread
distribut
infl
uenza
virus
contrast
studi
recent
report
found
pandem
detect
predominantli
isol
oseltamivir
recipi
unlik
recent
infl
uenza
virus
pandem
virus
seem
restrict
transmiss
among
human
fi
nding
indic
oseltamivir
use
respons
emerg
pandem
virus
perhap
widespread
distribut
pandem
although
reason
recent
season
infl
uenza
isol
lose
fi
tness
remain
unclear
function
defect
na
protein
caus
may
counteract
permiss
secondari
mutat
two
mutat
identifi
ed
season
infl
uenza
although
whether
amino
acid
correspond
posit
pandem
play
similar
role
unknown
na
protein
viru
v
residu
posit
respect
v
posit
ident
nonpermiss
amino
acid
sequenc
sporad
share
amino
acid
chang
observ
na
protein
pandem
virus
chang
appar
restor
viral
fi
tness
effi
cientli
transmiss
pandem
viru
found
observ
suggest
na
protein
recent
pandem
isol
like
possess
permiss
secondari
mutat
onlin
appendix
tabl
howev
recent
anim
studi
pandem
viru
shown
viral
fi
tness
transmiss
differ
os
pandem
viru
potenti
supersed
os
pandem
viru
nevertheless
pandem
supersed
os
pandem
human
inconsist
may
explain
differ
infecti
dose
use
anim
model
nai
assay
zanamivir
suscept
statist
analysi
identifi
ed
outlier
one
os
pandem
possess
mutat
report
affect
suscept
zanamivir
season
virus
two
pandem
isol
substitut
na
howev
whether
affect
zanamivir
suscept
unclear
also
assay
peramivir
suscept
repres
os
pandem
isol
data
suggest
pandem
viru
contain
substitut
possess
crossresist
peramivir
report
anoth
group
case
report
preliminari
nai
surveil
indic
group
high
risk
gener
resist
virus
fi
rst
patient
sever
compromis
suppress
immun
system
shed
viru
prolong
period
thu
increas
chanc
develop
resist
viru
report
resist
case
april
occur
immunocompromis
patient
second
group
person
receiv
postexposur
prophylaxi
take
subtherapeut
dose
mg
treatment
dosag
mg
regimen
may
partial
inhibit
viral
replic
thu
facilit
emerg
pandem
recommend
chemoprophylaxi
person
higher
risk
sever
complic
ill
group
observ
studi
found
pandem
viru
detect
sampl
collect
least
day
oseltamivir
treatment
prophylaxi
tabl
howev
frequenc
pandem
day
treatment
oseltamivir
could
calcul
lack
treatment
histori
data
time
consist
season
infl
uenza
pandem
virus
typic
emerg
day
oseltamivir
treatment
addit
also
observ
rapid
emerg
pandem
viru
within
hour
oseltamivir
exposur
nontheless
case
occur
untreat
patient
inde
pandem
oita
case
may
like
natur
occurr
awar
report
one
vietnam
one
hong
kong
natur
occur
pandem
untreat
patient
greatest
concern
regard
pandem
drugresist
virus
acquir
abil
transmit
effi
cientli
among
human
recent
season
infl
uenza
two
hospit
outbreak
unit
kingdom
unit
state
report
immun
system
patient
sever
compromis
suppress
indic
patient
increas
risk
emerg
pandem
viru
also
season
infl
uenza
viru
contrast
particular
attent
paid
vietnames
case
natur
occur
pandem
viru
caus
cluster
case
immunocompet
patient
histori
oseltamivir
use
despit
high
level
oseltamivir
use
japan
preval
pandem
remain
low
thu
oseltamivir
remain
fi
rst
option
treat
pandem
zanamivir
consid
immunocompromis
patient
addit
fi
rst
prioriti
prophylaxi
os
pandem
infect
vaccin
antivir
agent
convers
preclin
anim
model
show
pandem
high
potenti
acquir
transmiss
without
lose
viral
fi
tness
whether
pandem
may
acquir
effi
cient
transmiss
among
human
known
thu
vigil
monitor
pandem
infect
alter
transmiss
antigen
genet
characterist
essenti
